Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt)
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1266
https://www.valueinhealthjournal.com/article/S1098-3015(15)03342-2/fulltext
Title :
Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03342-2&doi=10.1016/j.jval.2015.09.1266
First page :
A474
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
765